Delaying the exchange subsidy suits
Kevin Outterson July 3, 2013
You might think that Cato would be pleased to see the large employer mandate delayed by a year (see Nicholas Bagley’s post). But you would be
You might think that Cato would be pleased to see the large employer mandate delayed by a year (see Nicholas Bagley’s post). But you would be
The following is a guest post by Nicholas Bagley, University of Michigan Assistant Professor of Law. What’s the legal basis for the administration’s decision to delay
There’s nothing magical about the individual mandate. No one loves it; no one champions it. It’s a solution (not the only one mind you) to
So, the employer mandate is delayed a year. Why not make it two, three, or infinitely more? Years ago, I wrote many posts questioning why
Related, I recommend “Cocktail Party Nephrology,” by David Goldfarb. It’s worth a read even if you’re not a stone maker. H/t Karan Chhabra. I make
Generic entry for small molecule drugs is controlled by Hatch-Waxman, allowing generic entry 10 – 20 years after FDA approval. For monoclonal antibodies and other
I’ve been working on a talk about the individual mandate and the employer penalty. In preparation, I was taking a look at the HHS “Guidance
Here’s the headline finding of my new paper in Health Services Research, coauthored with Steve Pizer and Roger Feldman: Controlling for quality, Medicare Advantage (MA)
We tend to equate “technology” with “high-tech,” e.g., devices built on microprocessors. That’s a mistake. “Technology” is broader than that, encompassing any practical application of
Interesting story at Kaiser Health News about many counties where no policies will be available in the exchanges: Tens of thousands of uninsured residents in
It’s been a while since I’ve seen news on the doc fix. And I didn’t remember it being time for the usual dance. So I
I just finished The Signal and the Noise, and I recommend it. Below are a few of my Kindle highlights, all direct quotes from the book.